A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Latest Information Update: 04 Mar 2025
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms TRuE AD1
- Sponsors Incyte Corporation
Most Recent Events
- 28 Feb 2025 According to an Incyte Corporation media release, ePoster featuring new data from this trial will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting, being held March 7-11, 2025, in Orlando.
- 16 Oct 2024 According to an Incyte media release, Health Canada has granted a Notice of Compliance for OPZELURA cream 1.5%, a non-steroidal topical Janus Kinase (JAK) inhibitor, for the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 12 years of age and older. This approval was based on TRuE-AD program.
- 15 Feb 2024 Results of pooled analysis (N=1208) from TRuE-AD1 and TRuE-AD2 studies assessing efficacy and tolerability of ruxolitinib cream published in the Journal of Dermatological Treatment.